VENODIOL-M
(Diosmin+Hesperidin)




COMPOSITION

1 tablet of Venodiol-M contains

Active substance: Diosmin 450 mg,

Hesperidin 50 mg,

Excipients: povidone K30, sodium croscarmellose, magnesium stearate, microcrystalline cellulose.

THERAPEUTIC INDICATIONS

- symptomatic therapy of organic and functional chronic venous insufficiency of the lower limbs (heaviness, edema and leg pains, trophic disturbances);

- symptomatic therapy of acute hemorrhoid.

CONTRAINDICATIONS

- Hypersensitivity to the drug or any drug components;

- age under 18.

ADVERSE EFFECTS

The following parameters of adverse reactions frequency are defined in the following way: common (≥ 1/100, < 1/10); uncommon (≥ 1/1000, < 1/100); rare (≥ 1/10000, < 1/1000); frequency unknown.

Nervous system: rare - dizziness, headache, general malaise.

GIT: common - diarrhea, dyspepsia, nausea, vomiting; uncommon - colitis.

Skin and subcutaneous reactions: rare - rash, urticaria, itching; frequency unknown – isolated edema of face, lips, eyelids; in isolated cases - angioedema.

DOSAGE AND ADMINISTRATION

Venodiol -M is administered orally, washing down with sufficient amount of water.

Venous insufficiency: 2 tablets daily (morning and evening);

Acute hemorrhoid: 3 tablets twice daily during the first four days, then 2 tablets twice daily during 3 days.

SPECIAL INDICATIONS

The administration of Venodiol-M treatment of acute hemorrhoid does not substitute basic therapy. The duration of treatment should be short. If the symptoms are not eliminated after the recommended therapy course, proctologic check-up should be performed, and the therapy should be reconsidered.

In case of disturbances of venous circulation, the maximum treatment effect is provided by combination of therapy and healthy (balanced) lifestyle: it is recommended to avoid long exposure to sun, long stay in upright position, as well as to decrease excessive body mass.

PREGNANCY AND LACTATION

Embryotoxic, mutagenic and teratogenic action of Venodiol-M have not been detected as a result of experimental and clinical trials. Trials with the involvement of women of third trimester pregnancy have proved the efficacy of Venodiol-M without any risk for fetus. Due to the absence of sufficient data regarding the penetration of Venodiol-M to breast milk, the administration of Venodiol-M during lactation is not recommended.

MANUFACTURED FORM AND PACKAGE

Tablets.

10 tablets in a blister.

3 or 6 blisters with a leaflet in a carton box.

Alimentary Tract and Metabolism

All Products
Bactamed
Cefamed
Clavomed Suspension
Clavomed Tablet
Doramycin
Fluzamed
Fosfomed
Levoximed Infusion
Levoximed Tablet
Lynozid
Merkacin
Orcipol
Ziromin

Home      |      Site Map      |      Terms of Use      |      Privacy Policy

2015 WORLD MEDICINE. All Rights Reserved.